• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:

    公开号:SU932988A3
    申请号:SU802969272
    申请日:1980-08-27
    公开日:1982-05-30
    发明作者:Веингер Эгберт；Майер Хорст；Боссерт Фридрих；Фатер Вульф；Товарт Робертсон；Штепель Курт；Казда Станислав
    申请人:Байер Аг (Фирма)；
    IPC主号:
    专利说明:

    The invention relates to a method for producing new optical active derivatives of 1,4-dihydropyridinecarboxylic acid of the general formula
    L10 g 5 : N e b and 1 (I) aboutTO - (! n e 10
    * where C ~ is methyl, ethyl or 2-methoxyethyl, which have pharmacological activity and can be used in medicine.
    ; A known method [1] for the preparation of racemates of asymmetric esters of 1,4-dihydropyridinecarboxylic acid of the formula n } e T 1G • n, (Hn- ^ n, n as where R has the above meanings, which consists in the fact that
    (VI) is reacted with an enaminocarboxylic acid ester of the general formula; CH 5 —C = Ch-Coor g wherein R ′ has the above meanings (1).
    Compounds of the general formula 1U have cardiovascular activity.
    The purpose of the invention is to obtain new derivatives of 1,4-dihydropyridinecarboxylic acid as agents that affect blood circulation.
    This goal is achieved ι way to obtain compounds of General formula (I), based on the well-known transesterification reaction [2}, which consists in the general formula
    Sn 3
    932988 that ester
    N02 • 4
    phenyl; methoxyl or methoxyl;
    where r 2 Ri - phenyl, is subjected to transesterification of spir. volume of the general formula
    R is OH (III) where R has the indicated meanings.
    PRI me R 1. Obtaining isopropyl methyl ester of (+) - 1,4-dihydro-2,6-dimethyl-4- (3 ″ nitroph. Nyl) pyridine-3,5 ~ dicarboxylic acid. 19 g (38 mmol) of the complex isopro-nnn- [2 (S) -methoxy-2-phenylethyl-D-eLira (+) - 1,4-dihydro-2,6-dimethyl-4- (3 Z nitrophenyl) - pyridine-3,5 “dicarboxylic acid is added to a solution of 0.87 g (38 mmol) of sodium in 50 ml of methanol and 50 ml of“ 1,2-dimethoxyethane.a and heated to boiling for 5 hours under nitrogen '. Then the solution is concentrated in vacuo to half the volume and acidified with dilute hydrochloric acid. After adding the same part of water, the mixture was extracted several times with methylene chloride, the extracts were dried over sodium sulfate and concentrated in vacuo. The solid residue is recrystallized from methanol '(crude product yield 5.5 g (39%), mp 134 -.
    136 C) and then purified by liquid chromatography on a column with a length of 250 mm and an inner diameter of 16 mm using mixtures of acetonitrile with water (45:55) as an eluent.
    Mp product 13o C.
    + 24.97 ° (c = 0.93 vol.%; Ethanol).
    PRI me R 2. Obtaining a complex, isopropyl methyl effir (-) - 1,4-dihydro-2,6-dimethyl-4- (3 '· -nitrophenyl) -pyridine-3,5-dicarboxylic acid. 16.5 g (33.4 mmol) of (-) - 1,4-dihydro-2,6-dimethyl-4 (3 Z- nitrophenyl) - isopropyl- [2 (R) -methoxy-2-denylethyl] ester complex - pyridine- 3,5_ dicarboxylic acid is added to a solution of 0.87 g (38 mmol) of sodium in 100 ml of methanol and heated to boiling for 24 hours in a nitrogen atmosphere. . After cooling, the solution is concentrated in vacuo to half the volume and acidified with dilute hydrochloric acid. After adding the same portion of water, the mixture was extracted several times with methylene chloride, the extracts were dried over sodium sulfate and concentrated in vacuo. The crystalline residue is suctioned off, recrystallized from methanol (yield of crude product 4.2 g 34%); so pl. 132-1 34 ° C) and purified by liquid chromatography under pressure as described in example 1.
    Mp 136 ° C.
    [oO ^ = -24.60 ° (c = 1.07 vol.%; ethanol).
    Example 3 · Preparation of (+) - 1,4-dihydro-2,6-dimethyl-4- (3-nitrophenyl) pyridin-3,5 “dicarboxylic acid ethyl isopropyl ester. 19 g (38 mmol) of isopropyl- {2 (S) -methoxy-2-phenylethyl) ether (+) “1, 4-dihydro-2,6-dimethyl-4- (3'-nitrophenyl) pyridine- 3,5_ dicarboxylic acid is added to a solution of 0.87 g (38 mmol) of sodium in 100 ml of ethanol and heated to boiling for 8 hours in a nitrogen atmosphere. -Then the solvent is distilled off in vacuo, the residue is dissolved in water, the mixture is acidified with dilute hydrochloric acid and extracted several times with methylene chloride. The resulting extracts are dried over sodium sulfate and concentrated in vacuo. The crystalline residue is filtered off with suction, recrystallized from methanol (crude product yield 4.1 g * 28%, mp 143-146 ° C) and purified by liquid chromatography under pressure as described in Example 1.
    Mp 140 ° C.
    '+ 4.61 ° (c = 0.46 vol.%;
    ethanol)
    PRI me R 4. Obtaining a complex of ethyl isobutyl ether (-) - T, 4-dihydro-2, 6-dimethyl-4- (3 / _ nit rhenyl) pyridin-3,5 “Dicarboxylic acid. 18.6 g (27.6 mmol) of isopropyl- [2 (R) -methoxy-2-phenylethyl) ether (-) - 1,4-dihydro-2,6-dimethyl-4- (3 / nitrophenyl) -pyridin-3,5 ~ dicarboxylic acid is added to a solution of 0.86 g (37.6 mmol) of sodium in 100 ml of ethanol and heated to boiling for 8 hours in a nitrogen atmosphere. Then the solution is concentrated in vacuo to half the volume, acidified with dilute hydrochloric acid, the same part of water is added and several times extracted.
    triturated with methylene chloride. The resulting extracts are dried with sodium sulfate and concentrated in vacuo. The resulting oily residue crystallizes, crystall. suction, recrystallized from methanol (crude yield
    2.8 g - 19.2%, mp 146-149 ° C) and purified by liquid chromatography under pressure as described in example 1.
    Mp 140 ° C.
    - 4.75 ° (c = 0.51 vol.%; Ethanol).
    PRI me R 5 · Obtaining complex 'isopropyl-2-methoxyethyl ether (+) - 1,4-dihydro-2,6-dimethyl-4- (3 L nitrophenyl) -pyridine-3,5-dicarboxylic acid. 24.7 g (50 mmol) of isopropyl-2 (S) -methoxy-2-phenylethyl ether (+) -1,4-dihydro-2,6-dime-; tyl-4- (3-nitrophenyl) -pyridin-3,5 ~ dicarboxylic acid is added to a solution of 1.4 g (61 mmol) of sodium in 230 ml of freshly distilled glycol monomethyl ether and the solution is stirred at 25 85 ° C for 8 hours in the atmosphere nitrogen. After cooling, the solvent is distilled off in vacuo, the residue is dissolved in water, the mixture is acidified with dilute hydrochloric acid and extracted several times with methylene chloride. The combined extracts are dried over sodium sulfate and concentrated. The resulting oily residue is triturated in a small amount of ether, and the product crystallizes. The resulting solid product is suctioned off (yield of crude product 15.1 g - 72%, mp 12b-129 ° C) and recrystallized from ethanol twice.
    Mp 134 ° C.
    [c0 £ ° = + 17.10 ° (c = 0.96 vol.%; ethanol).
    to
    3 $
    PRI me R 6. Obtaining complex isopropyl-2-methoxyethyl ether (-) - 1, 4-dihydro-2.b-dimethyl - ^ - O * -nitrophenyl) -pyridine-3,5 Dicarboxylic acid, 8.2 g (16.6 mmol) of (-) - 1,4-dihydro-2,6-dimethyl-4- (3 , _ nitrophenyl) -pyridin-3 isopropyl-2 (R) -methoxy-2-phenylethyl ester complex, 5 “dicarboxylic acid is added to a solution of 0.5 g (21.8 mmol) of sodium vvOmch. freshly distilled monomethyl ether and the solution was stirred at 85 ° C for 8 hours in a take-off atmosphere. After cooling, the solvent was distilled off. in vacuo, the residue is dissolved in water, the mixture is acidified with dilute hydrochloric acid and extracted several times with methylene chloride. The combined extracts are dried over sodium sulfate and concentrated. The oily residue soon crystallizes, and after adding a small amount of ether, the crystals are suctioned off (yield of the crude product 5.1 g - 73%) and recrystallized from ethanol twice. ''
    Mp 134 S.
    UJp ° = -16.9 ° C (c = 1.5 vol.%; Ethanol).
    Example 7 · Testing the compounds of General formula (I) for physiological activity.
    The activity of the new compounds, in the quality of blood circulation agents, is illustrated by the data given in the table.
    Changes in the action of 1,4-dihydropyridinecarboxylic acid heart rate in guinea pigs with barium inhibited heart rate by 50%.
    Example Concentration, molar solution The increase in the curve of the dose of action,% 1 1.410 8 78 2 1,5. Yu'9 73 3 4.9 xlO "9 89. 4 1.9, U-9 106 5 3.5U-9 . 85 6 2.7 i 10 ~ 9 94
    '932,988 derivatives of bonic acid
    权利要求:
    Claims (2)
    [1]
    Ruta methylene chloride. The resulting extracts are dried with sodium sulfate and concentrated in vacuo. The semi-oily oil residue crystallizes, the crystals are sucked off, recrystallized from methanol (the yield of the crude product is 2.8 g - 19.2%, mp. IB-C) and the liquid is purified (Noah by chromatography under the pressure described in example 1 T. t.L., - +, 75 (with 0.51 vol .;; ethanol). EXAMPLE 5- Preparation of (+) - 1, + - dihydro- 2,6-methoxyethyl ester. -dimethyl-4- (nitrophenyl) -pyridine-3,5 dicarboxylic acid. 2 +, 7 g (50 mmol) of isopropyl-2 (3) -methoxy-2-phenylethyl- (+) -1, - dihydro-2,6-dimethyl- - (3 -nitrophenyl) -pyridine-3,5 dicarboxylic acid added t, g (61 mmol) of sodium in 230 ml of freshly distilled monomethyl ether glycol and the solution is stirred at 85 ° C for 8 hours under nitrogen atmosphere. After cooling, the solvent is distilled off in vacuum, the residue is dissolved in - water, the mixture is acidified diluted with hydrochloric acid and extracted several times with methylene chloride. The combined extracts are dried over sodium sulfate and concentrated. The oily residue obtained is triturated in a small amount of ether, and the product crystallizes. The resulting solid product is sucked off (the yield of the crude product 15, G g - 72%, so pl. 12b-129 C) and recrystallized twice from ethanol. M.p. . + 17.10 (from 0.96% ethanol). PRI me R 6. Obtaining the isopropyl-2-methoxyethyl ester of (-) -, -dihydro-2,6-dimethyl- - (3-nitrophenyl) -pyridine-3.5 dicarboxylic acid, 8.2 g ( 16.6 mmol) of isopropyl-2 (K) -methoxy-2-phenylethyl ester of (-) -, 4-dihydro-2,6-dimethyl- - (3-nitrophenyl) -pyridine-3,5-dicarboxylic acid is added to a solution of 0.5 g (21.8 mmol) of sodium 80 ml of freshly distilled monomethyl ether and the solution is stirred at 85 ° C for 8 hours in an atmosphere of vzot. After cooling, the solvent is distilled off. under vacuum, the residue is dissolved in water, the mixture is acidified with dilute hydrochloric acid, and extracted several times with methylene chloride. The combined extracts are dried over sodium sulfate and concentrated. The oily residue crystallizes quickly, and after adding a small amount of ether, the crystals are sucked off (crude product yield 5.1 g 7 73) and recrystallized twice from ethanol. M.p. 13h pp. -16.9 C 1s 1.5; ethanol). Example 7. The test compounds of General formula (I) on the physiological activity. The activity of the new compounds, as agents affecting the blood circulation, is illustrated by the data given in the table. The change in the frequency of 1,4-dihydropyridinecarboxylic acid heart rate in a guinea pig with an inhibited number of heart contractions of barium by 50%. 7932 The claims of the method for obtaining optically active derivatives of 1, -dihydropyridinecarboxylic acid of the general formula .1 +) - 1,4-dihydro-2, 6-dimethyl-4-3-nitrophenyl) riipidine-3, 5-dicarboxylic acid of the general formula (II) where R is phenyl; methoxy or R - methoxy and p2 Phenyl, are transesterification with an alcohol of the general formula. R-OH where has the indicated meanings. Sources of information taken into account in the examination 1. German Patent R 2117571, cl. C 07I 211/90, published. 1979
    [2]
    2. Byuler K. and Pearson D. Organic syntheses. M., Mir, 1973, v. 2, p. 296.
    类似技术:
    公开号 | 公开日 | 专利标题
    SU932988A3|1982-05-30|Process for producing optically active derivatives of 1,4-dehydropiridinecarboxylic acid
    SU1428199A3|1988-09-30|Versions of method of producing derivatives of 2,2,3-iminobisethanol or acid-additive salts thereof,or stereochemical isomeric forms thereof
    EP0185429A1|1986-06-25|New bicyclic heteroaryl piperazines
    CA1233467A|1988-03-01|Phenyl tetrahydronaphthylcarboxylate derivatives
    KR20050084070A|2005-08-26|Drugs for chronic pain
    EP0249245A2|1987-12-16|Antihypertensive dihydropyridine derivatives
    FR2472561A1|1981-07-03|4-GUANIDINOMETHYLCYCLOHEXANE CARBOXYLIC ACID DERIVATIVES, PROCESS FOR PREPARING THEM AND THEIR THERAPEUTIC APPLICATION
    US4672071A|1987-06-09|Antihypertensive dihydropyridine compositions, optical isomers and intermediates
    RU2708243C1|2019-12-05|Method of producing a phenylalanine compound
    US7109242B2|2006-09-19|Carboxylic compound and medicine comprising the same
    US6013666A|2000-01-11|Oxirane carboxylic acid derivative and its manufacturing method
    US4571408A|1986-02-18|α,β-Dihydropolyprenyl derivatives for treating hepatitis
    EP1627866B1|2008-12-24|Carboxylic acid compound and medicine containing the same
    US4595690A|1986-06-17|Antihypertensive dihydropyridine derivatives
    SU1097195A3|1984-06-07|Process for preparing derivatives of 2-aminocarbonyl-oxyalkyl-1,4-dihydropyridine
    SU947160A1|1982-07-30|3-n-octyl-4-methyl-5-|-2-oxozolidone exhibiting vasodilatating activity
    RU2298549C2|2007-05-10|Method for preparing n-methyl-n-[|-1-phenyl-2-|-3-hydroxypyrrolidin-1-yl)ethyl]-2,2-diphenylacetamide as pure enantiomer
    EP0093945A2|1983-11-16|1,4-Dihydropyridine derivatives
    BE1004089A3|1992-09-22|DERIVATIVES | 3-Amino-2 PROPANE methoxymethylenemalonic 1-OL, A METHOD OF PREPARATION THEREOF SAME AND THERAPEUTIC COMPOSITIONS CONTAINING.
    SE443784B|1986-03-10|NEW ASSOCIATIONS WITH PHARMACOLOGICAL EFFECT
    PT87927B|1995-03-01|7- | ACIDS, OF ITS CORRESPONDING DELTA-LACTONES AND SALTS, AND OF PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
    US5037837A|1991-08-06|Phenoxypropylamine derivatives or salts thereof and antiulcer agents containing the same
    SU528878A3|1976-09-15|The method of obtaining | -deoxynormorphine or deoxynorcodeine derivatives, or their salts
    KR960016525B1|1996-12-14|Preparation process for dihydropyridine compound or its salt
    EP0288647B1|1992-04-08|Derivatives of 5-[2-|ethoxy]-p-cymene, process for their preparation, and medicaments containing these derivatives
    同族专利:
    公开号 | 公开日
    NZ194805A|1984-05-31|
    US4849433A|1989-07-18|
    AU545023B2|1985-06-27|
    NO802446L|1981-03-02|
    NO159928C|1989-02-22|
    PH17914A|1985-01-25|
    PH19006A|1985-12-03|
    AR228576A1|1983-03-30|
    DE3071186D1|1985-11-21|
    PT71724A|1980-09-01|
    DK160549B|1991-03-25|
    AT16101T|1985-11-15|
    AU6198280A|1982-03-25|
    NO159928B|1988-11-14|
    PL226503A1|1982-05-24|
    DK164158B|1992-05-18|
    IE50504B1|1986-04-30|
    US4988717A|1991-01-29|
    CA1142937A|1983-03-15|
    GR70080B|1982-07-27|
    PT71724B|1981-06-17|
    HU184821B|1984-10-29|
    JPS5636455A|1981-04-09|
    PL128310B1|1984-01-31|
    CS228506B2|1984-05-14|
    JPH07600B2|1995-01-11|
    IL60937A|1984-02-29|
    FI802717A|1981-03-02|
    IE801820L|1981-03-01|
    ZA805372B|1981-09-30|
    JPH05310694A|1993-11-22|
    FI78686B|1989-05-31|
    DK368480A|1981-03-02|
    DD154014A5|1982-02-17|
    EP0026317B1|1985-10-16|
    DK241390A|1990-10-05|
    DE2935451A1|1981-03-19|
    DK164158C|1992-10-12|
    EG15011A|1985-03-31|
    US4510310A|1985-04-09|
    FI78686C|1989-09-11|
    DK160549C|1991-09-16|
    ES8104228A1|1981-04-16|
    IL60937D0|1980-10-26|
    ES494614A0|1981-04-16|
    PH19749A|1986-06-23|
    EP0026317A1|1981-04-08|
    DK241390D0|1990-10-05|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    DE2117571C3|1971-04-10|1979-10-11|Bayer Ag, 5090 Leverkusen|Asymmetrical 1,4-dihydropyridine-33-dicarboxylic acid esters, process for their preparation and their use as pharmaceuticals|
    US3985758A|1973-02-20|1976-10-12|Yamanouchi Pharmaceutical Co., Ltd.|1,4-Dihydropyridine derivatives|
    DE2508181C2|1975-02-26|1988-12-01|Bayer Ag, 5090 Leverkusen, De|
    GB1552911A|1975-07-02|1979-09-19|Fujisawa Pharmaceutical Co|1,4 dihydropyridine derivatives and the preparation thereof|
    GB1591089A|1976-12-17|1981-06-10|Fujisawa Pharmaceutical Co|1,4-dihydropyridine derivatives and process for preparation thereof|
    SE429652B|1978-06-30|1983-09-19|Haessle Ab|2,6-dimethyl-4- -1,4-dihydropyridine-3,5-dicarboxylic acid 3-methyl 5-ethyl ester|
    DE2935451A1|1979-09-01|1981-03-19|Bayer Ag, 5090 Leverkusen|OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|DE2935451A1|1979-09-01|1981-03-19|Bayer Ag, 5090 Leverkusen|OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    JPS632431B2|1981-06-04|1988-01-19|Yoshitomi Pharmaceutical|
    JPS6330911B2|1981-06-04|1988-06-21|Yoshitomi Pharmaceutical|
    NZ201395A|1981-07-30|1987-02-20|Bayer Ag|Pharmaceutical compositions containing 1,4-dihydropyridines and certain of these dihydropyridines|
    GB2111978B|1981-10-19|1985-05-01|Maruko Pharmaceutical Co|1 4-dihydropyridine compounds|
    US4508719A|1982-06-03|1985-04-02|Pierrel S.P.A.|Hydroxyimino and alkoxyimino derivatives of 1,4-dihydropyridine and anti-hypertensive compositions|
    JPS5970667A|1982-10-15|1984-04-21|Kyowa Hakko Kogyo Co Ltd|1,4-dihydropyridine derivative|
    DE3248548A1|1982-12-29|1984-07-05|Heinrich Mack Nachf., 7918 Illertissen|ACYL DERIVATIVES OF 1,4: 3,6-DIANHYDRO-HEXITES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS|
    JPS59225162A|1983-06-03|1984-12-18|Kyowa Hakko Kogyo Co Ltd|1,4-dihydropyridine derivative|
    JPH0129187B2|1983-12-02|1989-06-08|Otsuka Pharma Co Ltd|
    IE57810B1|1984-03-27|1993-04-21|Delagrange Lab|1,4-dihydropyridine derivatives,their preparation and their use|
    US5364872A|1984-04-16|1994-11-15|Yamanouchi Pharmaceutical Co., Ltd.|Dihydropyridine-3,5-dicarboxylic acid ester derivatives|
    USRE34618E|1984-05-22|1994-05-24|Yamanouchi Pharmaceutical Co., Ltd.|Injection of nicardinpine hydrochloride and process for the production thereof|
    JPH0247964B2|1984-05-22|1990-10-23|Yamanouchi Pharma Co Ltd|
    DE3423105A1|1984-06-22|1986-01-02|Bayer Ag, 5090 Leverkusen|METHOD FOR PRODUCING OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE|
    JPH0153873B2|1984-08-07|1989-11-15|Otsuka Pharma Co Ltd|
    DE3431152A1|1984-08-24|1986-03-06|Cassella Ag, 6000 Frankfurt|METHOD FOR PRODUCING OPTICALLY ACTIVE, SUBSTITUTED 1,4-DIHYDROPYRIDINE AND THEIR USE AS A MEDICINAL PRODUCT|
    US4975440A|1984-09-28|1990-12-04|Byk Gulden Lomberg Chemische Fabrik Gmbh|Optically-active 1,4-dihydropyridine|
    DE3447169A1|1984-12-22|1986-07-03|Bayer Ag, 5090 Leverkusen|OPTICALLY ACTIVE NITRODIHYDROPYRIDINE, METHOD FOR THE PRODUCTION AND THEIR USE IN MEDICINAL PRODUCTS|
    JPH0455426B2|1985-01-09|1992-09-03|Teijin Ltd|
    US4771057A|1986-02-03|1988-09-13|University Of Alberta|Reduced pyridyl derivatives with cardiovascular regulating properties|
    DK142287A|1986-03-27|1987-09-28|Byk Gulden Lomberg Chem Fab|OPTIC ACTIVE 1,4-DIHYDROPYRIDINE DERIVATIVES|
    US4886819A|1986-08-27|1989-12-12|The Green Cross Corporation|Dihydropyridine derivatives and pharmaceutical composition thereof|
    JPH0686429B2|1986-08-27|1994-11-02|株式会社ミドリ十字|Dihydropyridine derivative|
    JPH0755955B2|1986-09-10|1995-06-14|日産化学工業株式会社|Optically active dihydropyridine-5-phosphonate|
    HU196755B|1986-09-16|1989-01-30|Gyogyszerkutato Intezet|Process for production of new substituated amilid derivatives and medical compositions containing them|
    US4920225A|1986-12-22|1990-04-24|Laboratoires Syntex S.A.|Resolution of 1,4-dihydropyridine derivatives|
    WO1988007525A1|1987-03-27|1988-10-06|Byk Gulden Lomberg Chemische Fabrik Gmbh|1,4-dihydropyridine enantiomers|
    EP0287828A1|1987-03-27|1988-10-26|Byk Gulden Lomberg Chemische Fabrik GmbH|Intermediates and their preparation|
    US4889866A|1987-06-11|1989-12-26|SyntexInc.|Arylsulfonyl dihydropyridine derivatives|
    JPS6429359A|1987-07-24|1989-01-31|Teijin Ltd|1,4-dihydropyridine derivative and production thereof|
    DE3821334A1|1988-06-24|1989-12-28|Bayer Ag|1,4-DIHYDROPYRIDINE-THREONINE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, INTERMEDIATE PRODUCTS AND THEIR USE AS MEDICINAL PRODUCTS|
    US5158963A|1989-08-02|1992-10-27|Kaken Pharmaceutical Co., Ltd.|1-4-dihydropyridine derivative, process for preparing the same and pharmaceutical composition containing the same|
    DE4011106A1|1990-04-06|1991-10-10|Bayer Ag|NEW HETEROCYCLIC SUBSTITUTED DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE IN MEDICINAL PRODUCTS|
    DE4117750A1|1991-05-30|1992-12-24|Bayer Ag|NEW 2-AMINO-5-CYANO-1,4-DIHYDROPYRIDINE, PROCESS FOR THEIR PREPARATION AND THEIR USE IN MEDICINAL PRODUCTS|
    US5834496A|1991-12-02|1998-11-10|Sepracor, Inc.|Methods for treating hypertension using optically pure S felodipine|
    AT399718B|1992-04-16|1995-07-25|Lek Tovarna Farmacevtskih|INCLUSION COMPLEXES OF OPTICALLY ACTIVE AND RACEMIC 1,4-DIHYDROPYRIDINES WITH METHYL-BETA-CYCLODEXTRIN OR OTHER CYCLODEXTRINE DERIVATIVES, A METHOD FOR THE PRODUCTION OF OPTICALLY ACTIVE DIHYDROPYRIDE-DOMETHYL-DOMETHYL-DOMETHYL-DOMETHYL POWERS|
    DE4236707A1|1992-10-30|1994-05-05|Bayer Ag|4-heterocyclyl substituted dihydropyridines|
    US6001857A|1992-10-30|1999-12-14|Bayer Aktiengesellschaft|Heterocyclyl substituted dihydropyridines|
    ES2096179T3|1992-10-30|1997-03-01|Bayer Ag|DIHYDROPYRIDINES REPLACED IN POSITION 4 WITH A HETEROCICLILFENILO.|
    DE4342193A1|1993-12-10|1995-06-14|Bayer Ag|Aryl substituted alkoxycarbonyl-1,4-dihydropyridine-5-carboxylic acid esters|
    DE4342196A1|1993-12-10|1995-06-14|Bayer Ag|New 4-phenyl-substituted 1,4-dihydropyridines|
    EE03192B1|1993-12-10|1999-06-15|Bayer Aktiengesellschaft|Isopropyl-4--1,4-dihydro-2,6-dimethylpyridine-3,5-dicarboxylate, its enantiomers and intermediate, methods for their preparation and use|
    PT657432E|1993-12-10|2003-07-31|Bayer Ag|PHENYL-SUBSTITUTED 1,4-DIHYDROPYRIDINES WITH CEREBRAL ACTIVITY|
    US5478848A|1994-01-26|1995-12-26|Bayer Corporation|Inhibition of arthritis by L-type calcium channel antagonists nimodipine, nisoldipine and nifedipine|
    DE19532320A1|1995-09-01|1997-03-06|Bayer Ag|Process for the preparation of optically active ortho-substituted 4-aryl-dihydropyridines|
    JPH11106375A|1997-08-18|1999-04-20|Pfizer Pharmaceut Inc|Optically active 1,4-dihydropyridine compound as bradykinin antagonist|
    US20100247646A1|2009-03-26|2010-09-30|Ranbaxy Laboratories Limited|Extended release tablets of nisoldipine|
    法律状态:
    优先权:
    申请号 | 申请日 | 专利标题
    DE2935451A|DE2935451A1|1979-09-01|1979-09-01|OPTICALLY ACTIVE 1,4-DIHYDROPYRIDINE, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS A MEDICINAL PRODUCT|
    [返回顶部]